You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for bazedoxifene acetate; estrogens, conjugated

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00367536 ↗ Study Evaluating Three Bazedoxifene/Conjugated Estrogens Combination Tablet Formulations Versus BZA Oral Solution Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 1 2006-08-01 This study involves the experimental drug bazedoxifene acetate/conjugated estrogens (also called BZA/CE). This drug is not approved by the Food and Drug Administration (FDA). About 24 subjects will take part in this study. Each subject's participation in this study will last for about 10 weeks. During this study, each subject will receive 3 different types of BZA/CE tablets plus an oral solution containing only BZA. The purpose of this study is to learn how the tablet dosage forms dissolve and are absorbed by the body compared to the BZA oral solution. In addition, information will also be learned about the safety and tolerability of these dosage forms given to healthy postmenopausal women.
NCT00396799 ↗ Bioequivalence Study Of Bazedoxifene/Conjugated Estrogen Tablets In Postmenopausal Women Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 1 2006-11-01 The primary objective is to evaluate the bioequivalence between bazedoxifene/conjugated estrogens tablets produced using the current manufacturing process to bazedoxifene/conjugated estrogens tablets produced using a new manufacturing process
NCT00465075 ↗ Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Fed and Fasting in Healthy, Postmenopausal Women Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 1 2007-03-01 The primary objective is to determine the effect of a high-fat meal on the bioavailability and PK of a single, oral dose of BZA/CE (PNP) 20mg/0.625 strength tablet, assessing both the BZA and CE components.
NCT00774267 ↗ Study Evaluating Changes In Mammographic Breast Density Completed Pfizer 2009-01-01 The objective of the study is to evaluate quantitative changes in mammographic breast density from baseline to 24 months in postmenopausal women receiving daily doses of either BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene or placebo. The primary endpoint in this study is the change in mammographic breast density between baseline and month 24 for each group.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for bazedoxifene acetate; estrogens, conjugated

Condition Name

Condition Name for bazedoxifene acetate; estrogens, conjugated
Intervention Trials
Healthy 1
Menopause 1
Osteoporosis 1
Postmenopause 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for bazedoxifene acetate; estrogens, conjugated
Intervention Trials
Osteoporosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for bazedoxifene acetate; estrogens, conjugated

Trials by Country

Trials by Country for bazedoxifene acetate; estrogens, conjugated
Location Trials
United States 17
Norway 1
Netherlands 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for bazedoxifene acetate; estrogens, conjugated
Location Trials
Florida 2
Virginia 1
Texas 1
South Carolina 1
Pennsylvania 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for bazedoxifene acetate; estrogens, conjugated

Clinical Trial Phase

Clinical Trial Phase for bazedoxifene acetate; estrogens, conjugated
Clinical Trial Phase Trials
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for bazedoxifene acetate; estrogens, conjugated
Clinical Trial Phase Trials
Completed 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for bazedoxifene acetate; estrogens, conjugated

Sponsor Name

Sponsor Name for bazedoxifene acetate; estrogens, conjugated
Sponsor Trials
Wyeth is now a wholly owned subsidiary of Pfizer 3
Pfizer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for bazedoxifene acetate; estrogens, conjugated
Sponsor Trials
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.